Expression and Clinical Significance of NUF2 in Kidney Renal Clear Cell Carcinoma

Overview

Journal Transl Androl Urol

Date 2021 Nov 4

PMID 34733658

Citations 4

Authors

Li Shan

Xiao-Li Zhu

Yuan Zhang

Guo-Jian Gu

Xu Cheng

Affiliations

Soon will be listed here.

Abstract

Background: To explore the expression and clinical significance of the cytokinesis-related gene in kidney renal clear cell carcinoma (KIRC).

Methods: Gene expression profiles of KIRC patients were extracted from The Cancer Genome Atlas (TCGA) database. The differences in mRNA expression between patients and controls, as well as the relationship between the clinical characteristics and overall survival of the patients, were analyzed. The expression of NUF2 protein in 83 cancer tissues and para-cancerous tissues was detected to analyze the relationship with clinical characteristics. Gene Set Enrichment Analysis (GSEA) was used to investigate the possible regulatory pathways of the in the development of KIRC.

Results: mRNA was significantly higher in patients with KIRC, and the prognosis of patients with high expression of mRNA was significantly worse than those with low expression, and was related to the AJCC stage, T stage, lymph node metastases, and distant metastases. mRNA was an independent prognostic risk factor for KIRC patients. The expression of NUF2 protein was significantly higher in KIRC patients than in paraneoplastic tissues and was markedly associated with the pathological grade. In addition, the high expression of was associated with the upregulation of pathways such as homologous recombination and DNA replication.

Conclusions: may act as an independent prognostic biomarker for predicting the survival of KIRC patients.

Citing Articles

Low expression of PRRG2 in kidney renal clear cell carcinoma: an immune infiltration-associated prognostic biomarker.

Tang G, Ding G, Wu G, Wang X, Wang T, Zou Q Discov Oncol. 2024; 15(1):9.

PMID: 38227081 PMC: 10792142. DOI: 10.1007/s12672-024-00864-x.

NUF2 Promotes Breast Cancer Development as a New Tumor Stem Cell Indicator.

Deng Y, Li J, Zhang Y, Hu H, Wan F, Min H Int J Mol Sci. 2023; 24(4).

PMID: 36835637 PMC: 9965662. DOI: 10.3390/ijms24044226.

NUF2 overexpression contributes to epithelial ovarian cancer progression ERBB3-mediated PI3K-AKT and MAPK signaling axes.

Leng R, Meng Y, Sun X, Zhao Y Front Oncol. 2023; 12:1057198.

PMID: 36620547 PMC: 9811817. DOI: 10.3389/fonc.2022.1057198.

Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma.

Li Z, Ma Z, Xue H, Shen R, Qin K, Zhang Y Front Genet. 2022; 13:917150.

PMID: 35873497 PMC: 9305311. DOI: 10.3389/fgene.2022.917150.

References

Nie C, He T, Zhang W, Zhang G, Ma X . Branched Chain Amino Acids: Beyond Nutrition Metabolism. Int J Mol Sci. 2018; 19(4). PMC: 5979320. DOI: 10.3390/ijms19040954. View

Jiang X, Jiang Y, Luo S, Sekar K, Koh C, Deivasigamani A . Correlation of NUF2 Overexpression with Poorer Patient Survival in Multiple Cancers. Cancer Res Treat. 2021; 53(4):944-961. PMC: 8524009. DOI: 10.4143/crt.2020.466. View

Liu Q, Dai S, Li H, Dong L, Peng Y . Silencing of NUF2 inhibits tumor growth and induces apoptosis in human hepatocellular carcinomas. Asian Pac J Cancer Prev. 2014; 15(20):8623-9. DOI: 10.7314/apjcp.2014.15.20.8623. View

Sansregret L, Vanhaesebroeck B, Swanton C . Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018; 15(3):139-150. DOI: 10.1038/nrclinonc.2017.198. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Liu D, Ding X, Du J, Cai X, Huang Y, Ward T . Human NUF2 interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment. J Biol Chem. 2007; 282(29):21415-24. DOI: 10.1074/jbc.M609026200. View

Sugimasa H, Taniue K, Kurimoto A, Takeda Y, Kawasaki Y, Akiyama T . Heterogeneous nuclear ribonucleoprotein K upregulates the kinetochore complex component NUF2 and promotes the tumorigenicity of colon cancer cells. Biochem Biophys Res Commun. 2015; 459(1):29-35. DOI: 10.1016/j.bbrc.2015.02.043. View

Liu D, Xu X, Wen J, Xie L, Zhang J, Shen Y . Integrated Genome-Wide Analysis of Gene Expression and DNA Copy Number Variations Highlights Stem Cell-Related Pathways in Small Cell Esophageal Carcinoma. Stem Cells Int. 2018; 2018:3481783. PMC: 6136462. DOI: 10.1155/2018/3481783. View

Mollica V, Di Nunno V, Massari F . Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma. Chin Clin Oncol. 2019; 8(S1):S21. DOI: 10.21037/cco.2019.04.05. View

10.

Ren L, Chen L, Wu W, Garribba L, Tian H, Liu Z . Potential biomarkers of DNA replication stress in cancer. Oncotarget. 2017; 8(23):36996-37008. PMC: 5514887. DOI: 10.18632/oncotarget.16940. View

11.

Huang S, Qian J, Yuan B, Lin Y, Ye Z, Huang S . SiRNA-mediated knockdown against NUF2 suppresses tumor growth and induces cell apoptosis in human glioma cells. Cell Mol Biol (Noisy-le-grand). 2014; 60(4):30-6. View

12.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

13.

Li C, Liu F, Huang D, Wu Y, Wang Z, Xu Y . The correlation between DNA mismatch repair status and the clinicopathological and molecular features of Chinese sporadic colorectal cancer. Transl Cancer Res. 2022; 9(1):137-144. PMC: 8797765. DOI: 10.21037/tcr.2019.11.24. View

14.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

15.

Hu P, Chen X, Sun J, Bie P, Zhang L . siRNA-mediated knockdown against NUF2 suppresses pancreatic cancer proliferation in vitro and in vivo. Biosci Rep. 2014; 35(1). PMC: 4293903. DOI: 10.1042/BSR20140124. View

16.

Venkitaraman A . Tumour suppressor mechanisms in the control of chromosome stability: insights from BRCA2. Mol Cells. 2014; 37(2):95-9. PMC: 3935635. DOI: 10.14348/molcells.2014.2346. View

17.

Sun J, Chen J, Wang Z, Deng Y, Liu L, Liu X . [Expression of NUF2 in breast cancer and its clinical significance]. Nan Fang Yi Ke Da Xue Xue Bao. 2019; 39(5):591-597. PMC: 6743945. DOI: 10.12122/j.issn.1673-4254.2019.05.15. View

18.

Harlander S, Schonenberger D, Toussaint N, Prummer M, Catalano A, Brandt L . Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat Med. 2017; 23(7):869-877. PMC: 5509015. DOI: 10.1038/nm.4343. View

19.

Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N . Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn. 2018; 18(7):645-655. DOI: 10.1080/14737159.2018.1490179. View

20.

Obara W, Sato F, Takeda K, Kato R, Kato Y, Kanehira M . Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017; 108(7):1452-1457. PMC: 5497926. DOI: 10.1111/cas.13278. View